Evidence map›Paper›PMID 29156767›Full record

ArticleOncotarget2017

Enhancing conventional chemotherapy drug cisplatin-induced anti-tumor effects on human gastric cancer cells both

Jingjing Ma, Xue Hu, Jiao Li, Dandan Wu, Qingzhi Lan, Qian Wang, Shan Tian, Weiguo Dong

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.

0numbers the graph read from it
0cells of the map it votes in
22citing papers in PubMed
5.1field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

22 citing papers in PubMed, 39 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Thymoquinone, as a Novel Therapeutic Candidate of Cancers.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jingjing MaDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Xue HuDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Jiao LiDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Dandan WuDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Qingzhi LanDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Qian WangDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Shan TianDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Weiguo DongDepartment of Gastroenterology, Renmin Hospital of Wuhan University, Wuhan, Hubei Province, China.
Renmin Hospital of Wuhan University · CNWuhan University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Combination chemotherapy regimen with several anti-tumor drugs is a strategy to improve outcome. Thymoquinone (TQ) has been reported to exert biological activity on various types of human cancers without obvious toxicity. However, only few studies showed the anti-tumor effects of TQ combination with cisplatin on gastric cancer (GC). Here, we showed pretreatment with 5μM TQ significantly increased the apoptotic effects induced by cisplatin on GC cell lines. Combined treatment of cisplatin with TQ represented a significantly superior tumor suppression effect than either agent alone in a xenograft tumor mouse model. Interestingly, TQ pretreatment following cisplatin caused a significant increase in the levels of PTEN, an obvious decrease in p-AKT, CyclinD1, P-glycoprotein (P-gp), meanwhile, TQ and cisplatin also led to an increase in Bax, Cyt C, AIF, cleaved caspase 9, and cleaved caspase 3, and a decrease in Bcl-2, procaspase-9, procaspase-3. Moreover, results

Indexed as

cisplatindrug sensitivitygastric cancerPTENthymoquinone

Identifiers

PMID29156767
PMCPMC5689657
OpenAlexW2750961797

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.